Antihistamines, Amantadine and Evolution of COVID-19

Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05504057

Enrollment

140660

Registered

2022-08-17

Start date

2020-03-01

Completion date

2028-02-24

Last updated

2026-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

antihistamines, amantadine, hospital admissions, survival

Brief summary

The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.

Detailed description

BACKGROUND: According to previous reports, all 84 eldery residents in nuersing homes in Yespes (Toledo, Spain), had a 100% of positive serology for COVID-19 in June 2020, but none died nor hospitalized after receiving early treatment with antihistamines. Other case reports have suggested a protective role of amantadine, since infected patients showed a very mild COVID19 infection. OBJECTIVES.Determine the role of antihistamines and amantadine in the evolution of COVID19. METHODS. Describe the rate of hospitalization, ICU, survival, postcovid syndrome and thrombosis among COVID 19 cases having antihistamines and amantadine as chronic treatments. The rates would be stratified by age groups and compared with the same age groups of the population assigned to the public free Access Terrassa Health Consortium.

Interventions

DRUGAntihistamine

Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines

DRUGAmantadine

Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

Patients having chronic treatment with antihistamines or amantadine -

Exclusion criteria

None \-

Design outcomes

Primary

Measure	Time frame	Description
Hospital Admissions.	from march 2020.	Rate of Hospitalization among COVID 19 infections

Secondary

Measure	Time frame	Description
Survival	from march 2020	Survival among COVID1 hospitalized cases.
Symptomatic infection	from march 2020	Patients suffering a symptomatic COVID19 infection within a determinate age group
Postcovid syndrome	from april 2020	Patients developing postcovid syndrome after COVID19 infection
Thrombosis	from april 2020	Patients developing thrombosis (with particular assessment of stroke, cardiac infarction, retinal vessels and pulmonary embolism)

Countries

Spain

Contacts

CONTACTAnna Puigdellivol, Ph.D

apuigdellivol@cst.cat34-93-5884555

PRINCIPAL_INVESTIGATORAnna Puigdellívol, PhD

Terrassa Health Consortium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026